Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Natural History Study of Usher Syndrome ( Light4Deaf )

Natural History Study of Usher Syndrome in a Cohort of Patients Followed Longitudinally for 5 Years

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Clinical centres in the LIGHT4DEAF consortium have developed and will continue to improve a reliable, early molecular diagnosis and protocols for full clinical characterisation of Usher syndrome, which will be valuable for the foreseen USH clinical trials. The clinical arm of the project aims at performing a deep-phenotyping of retinal degeneration, hearing loss, vestibular dysfunction, neurocognitive ability of subects with a molecular diagnosis of any Usher syndrome. Functional and structural parameters for retinal, auditory, and vestibular impairments are followed overtime to document the natural history of the disease and establish relevant clinical endpoint for disease progression that may be useful for future clinical trials.

Who May Be Eligible (Plain English)

Who May Qualify: - Patient with a molecular diagnosis of Usher syndrome type I, II or III or a clinical diagnosis of Usher syndrome type I, II or III which will then be confirmed by a molecular diagnosis - Health insurance beneficiary - willing to sign a consent form signed by the patient or their legal representatives Who Should NOT Join This Trial: • Patient or his/her legal representatives unable to understand the study and for whom willing to sign a consent form cannot be obtained Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patient with a molecular diagnosis of Usher syndrome type I, II or III or a clinical diagnosis of Usher syndrome type I, II or III which will then be confirmed by a molecular diagnosis * Health insurance beneficiary * Informed consent signed by the patient or their legal representatives Exclusion Criteria: • Patient or his/her legal representatives unable to understand the study and for whom informed consent cannot be obtained

Locations (4)

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Paris, France
CHU Pitié Salpêtrière
Paris, France
CHU Necker
Paris, France
CHU Robert Debré
Paris, France